Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.20
Views: 201
Rating:

Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA

Dr Hans Hammers speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the RADVAX trial for kidney cancer.

RADVAX looks to combine standard of care ICI (nivolumab/ipilimumab) with high dose stereotactic radiation to increase the response rate.

The results look promising, but the study is small, so Dr Hammers hopes to see if these results hold up against a larger cohort.

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation